secwatch.observer — SEC 8-K summary
======================================

Issuer:     DAXOR CORP (DXR)
CIK:        0000027367
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0001493152-24-011110
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Daxor acquires worldwide rights to Volumex, Megatope, and Glofil from Iso-Tex Diagnostics
--------------------------------------------------------------------------------

- No upfront payment; seller-financed with monthly installments starting after manufacturing transition in 6–9 months.
- Deal expected to be immediately accretive and cash flow positive due to higher margins from in-house production.
- Glofil (GFR diagnostic) adds recurring revenue stream and cross-selling opportunity to existing hospital customers.
- Volumex and Megatope radiopharmaceuticals for blood volume analysis will be produced at Daxor's Oak Ridge facility.
- Transaction subject to customary closing conditions including applicable regulatory approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/27367/000149315224011110/0001493152-24-011110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/27367/000149315224011110/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-011110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer